Resistencia al ácido acetilsalicílico como antiagregante plaquetario en pacientes con enfermedad trombótica
| dc.contributor.advisor | Salazar Sánchez, Lizbeth | es_CR |
| dc.contributor.author | López Cardoza, Hazell | es_CR |
| dc.date.accessioned | 2014-06-09T18:46:20Z | |
| dc.date.accessioned | 2021-06-16T23:18:07Z | |
| dc.date.available | 2014-06-09T18:46:20Z | |
| dc.date.available | 2021-06-16T23:18:07Z | |
| dc.date.issued | 2005 | es_CR |
| dc.description | Tesis (licenciatura en microbiología)--Universidad de Costa Rica, Facultad de Microbiología, 2005. | es_CR |
| dc.description.abstract | Acetylsalicylic acid or aspirin is one of anti-inflammatory no steroidal drugs which antipyretic, analgesic and anti-inflammatory properties are possible because irreversibly inhibits cyclooxygenase. This enzyme has two different isoform, the first is constitutively found by natural form in severa1 kinds of tissues and cell. The second one is going to be inducing in presence of pro-inflammatory or mitogenic stimulus. Aspirin has been used as antiplatelet drug in people with cardiovascular disease during last decades. Anti-inflammatory effects are possible by COX-2 inhibition when high doses are been used. However, afinity for COX-1 is 50 to 100 times bigger and it is responsible for the aspirin's antiplatelet properties. Lastly, 45% of patients in antiplatelet therapy have suffered recurrent vascuiar events that indicate development of aspirin resistance in some persons. For the moment, the cause is unknown but a number of possible explanations have been raised. | es_CR |
| dc.description.procedence | UCR::Docencia::Salud::Facultad de Microbiología | es_CR |
| dc.identifier.uri | https://repositorio.sibdi.ucr.ac.cr/handle/123456789/1588 | |
| dc.language.iso | spa | es_CR |
| dc.subject | SISTEMA CARDIOVASCULAR - ENFERMEDADES | es_CR |
| dc.subject | ASPIRINA | es_CR |
| dc.title | Resistencia al ácido acetilsalicílico como antiagregante plaquetario en pacientes con enfermedad trombótica | es_CR |
| dc.type | proyecto fin de carrera | es_CR |
Archivos
Bloque original
1 - 1 de 1